Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CCR1 | P32246 | 3/20 | 0.55 |
| ▸ | CCR5 | P51681 | 3/20 | 0.55 |
| ▸ | CCR8 | P51685 | 3/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29726791 | 1.00 | GRM5 (0.62) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL26824783 | 0.91 | GRM5 (0.57) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL31039976 | 0.85 | GRM5 (0.56) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL29679578 | 0.85 | KDM4E (0.62) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL502867 | 0.85 | KDM4E (0.62) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL15683870 | 0.84 | GRM5 (0.67) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL30340631 | 0.84 | GRM5 (0.67) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL15684056 | 0.84 | GRM5 (0.62) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL8429326 | 0.83 | CCR1 (0.64) | GRM5PKMTP53SMN1; SMN2NPC1 | |
| SCHEMBL16352566 | 0.83 | CCR1 (0.64) | GRM5PKMTP53SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070349-A | Organic light-emitting compound and organic electroluminescent device comprising the same | 索路思高新材料有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-115322192-A | Pyrrolo [3,4-b ] pyridine derivatives, and synthesis method and application thereof | 重庆文理学院 | 2022-11-11 | — | — | CN | disclosed |
| CN-105992767-B | WNT pathway modulators | 新加坡科技研究局 | 2019-06-21 | — | — | CN | disclosed |
| US-9682958-B2 | Ligands and their preparation | MERCK PATENT GMBH (DE) | 2017-06-20 | — | — | US | disclosed |
| US-9682958-B2 | Ligands and their preparation | MERCK PATENT GMBH (DE) | 2017-06-20 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| CN-105899488-A | Process for fluorinating compounds | 美国陶氏益农公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20150175574-A1 | Ligands And Their Preparation | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175574-A1 | Ligands And Their Preparation | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-7442797-B2 | Platinum complex and light emitting device | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| US-7442797-B2 | Platinum complex and light emitting device | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| WO-2007129810-A1 | SYNTHESIS OF VINYLPHENYLPYRIDINE AND LIVING ANIONIC POLYMERIZATION | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-11-15 | — | — | WO | disclosed |
| US-20070103060-A1 | Platinum complex and light emitting device | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070103060-A1 | Platinum complex and light emitting device | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070103060-A1 | Platinum complex and light emitting device | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-05-10 | — | — | US | disclosed |
| CN-1875026-A | Platinum complex and luminescent element | TAKASAGO PERFUMERY CO LTD (JP) | 2006-12-06 | — | — | CN | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060202197-A1 | Platinum complex and light-emitting device | TAKASAGO INTERNATIONAL CORPORATION | 2006-09-14 | — | — | US | disclosed |
| EP-1683804-A2 | PLATINUM COMPLEX AND LUMINESCENT ELEMENT | Takasago International Corporation (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070103060-A1 | Platinum complex and light emitting device | UBE2D3, PCID2, CCND2 | GRM5 1971/4885PKM 3822/4885TP53 2075/4885 |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | GRM5 1954/4885PKM 604/4885TP53 32/4885 |
| US-20060202197-A1 | Platinum complex and light-emitting device | RAD1, RAD51, UACA | GRM5 2608/4885PKM 3533/4885TP53 1619/4885 |
| US-20150175574-A1 | Ligands And Their Preparation | PNMT, DNMT1, DNMT3A | GRM5 395/4885PKM 1916/4885TP53 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.